Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 5, Issue 6, Pages 629-647Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECP.12.55
Keywords
bioavailability; corticosteroids; degeneration; dexamethasone; inflammation; intraocular; polymer matrix; visual acuity; vitreous
Categories
Funding
- Allergan, Inc.
Ask authors/readers for more resources
The challenge in the treatment of chronic retinal diseases is to deliver effective therapy to the target tissues in the back of the eye while limiting drug exposure in nontarget tissues. Intravitreal placement provides the most targeted drug delivery, but repeated penetration of the globe to deliver intravitreal therapy can pose safety risks. A more effective strategy for the treatment of chronic retinal diseases would be to combine intravitreal placement with sustained drug delivery. The dexamethasone intravitreal (DEX) implant is a biodegradable sustained-release intravitreal drug delivery system that is approved for the treatment of macular edema following branch or central retinal vein occlusion and for noninfectious uveitis affecting the posterior segment of the eye. A single DEX implant has been shown to provide clinical benefits for up to 6 months in eyes with retinal vein occlusion or intermediate or posterior uveitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available